We suggest that trametinib, an immune modulating drug, may be utilized to protect against further immune-mediated insults to cartilage and bone through inhibiting ERK-mediated inflammation in post-infectious MRSA septic arthritis. This evidence concerns the gene MAPK1 and bacterial arthritis.